<DOC>
	<DOCNO>NCT00099671</DOCNO>
	<brief_summary>The purpose study determine safety single , under-the-skin dose interleukin-7 ( IL-7 ) HIV infected people currently take anti-HIV drug .</brief_summary>
	<brief_title>Safety Interleukin-7 HIV Infected People Currently Taking Anti-HIV Drugs</brief_title>
	<detailed_description>CD4 count best predictor HIV disease progression . IL-7 play important role immune system function , especially development T cell , include CD4 cell . IL-7 may improve HIV-specific immune response increase number CD4 cell boost immune response . This study evaluate safety single IL-7 dose give skin HIV infect patient currently potent antiretroviral therapy ( ART ) . This study last 13 week . Participants stratify two group viral load : Stratum 1 participant viral load le 50 copies/ml , Stratum 2 participant viral load 50 50,000 copies/ml . Participants receive one dose either IL-7 placebo study entry . Five different dosing level IL-7 test sequentially strata . Dose escalation occur independently stratum enrollment stratum end maximum-tolerated dose reach . As 10/23/06 , due adverse event associate 60 mcg/kg dose level , participant receive 30 mcg/kg dose level , dose escalation . New participant enroll Stratum 2 . There 9 study visit ; medical medication history , physical exam , lymph node spleen assessment , blood collection occur visit . Participants undergo electrocardiogram study entry Day 1 , spleen ultrasound Week 3 . Urine collection occur Day 4 Weeks 2 3 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>HIV infect Currently ART consist least 3 antiretroviral drug least 12 month prior study entry stable ( change dose ) treatment least 3 month prior study entry CD4 count 100 cells/mm3 within 42 day study entry Viral load 50,000 copies/ml less within 42 day study entry Willing use acceptable form contraception Participants Category C AIDSdefining illness 12 month prior study entry may eligible long CD4 count 200 cells/mm3 screening . Participants Kaposi 's sarcoma may also eligible study . Lymphadenopathy great 2.0 cm Known allergy sensitivity study drug formulation Current drug alcohol abuse Serious illness hospitalization , opinion site investigator , may interfere study result Prior use interleukin Systemic cancer chemotherapy , systemic investigational agent , immunomodulators ( e.g. , growth factor , systemic corticosteroid , HIV vaccine , immune globulin , interferon ) within 90 day prior study entry Heparin within 96 hour prior study entry , anticipate need heparin within 96 hour study injection History cancer ( except basal carcinoma skin Kaposi 's sarcoma ) Enlargement spleen History hypercoagulability ( deep vein thrombosis pulmonary embolism ) History seizure disorder History extensive psoriasis , Crohn 's disease , uveitis , autoimmune disease induce severe complication Significant psychiatric , cardiac , pulmonary , thyroid , renal , neurological disease require therapy Positive hepatitis B surface antigen positive hepatitis C antibody screen Plan start new ART within 8 week study entry Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>